Payment overview · 2025
General Payments
$8,772.36
66 reported records · 11 companies
Healthcare provider profile · identity verified
Vasili Lendel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LITTLE ROCK, AR · NPI 1720104516
Verified facts
What the public records show
CMS Open Payments records show Vasili Lendel, MD received $8,772.36 in general payments during 2025 across 66 reported records.
Shockwave Medical, Inc accounted for 83.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 746 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 746 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $7,303.89 | 83.3% | 16 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $349.73 | 4.0% | 6 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $249.14 | 2.8% | 2 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $244.37 | 2.8% | 15 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $189.16 | 2.2% | 11 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $152.15 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.37 | 1.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.42 | 0.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.76 | 0.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.44 | 0.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.93 | 0.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $6,050.00 | 4 |
| Food and Beverage | $2,276.11 | 61 |
| Travel and Lodging | $446.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $7,303.89 | 16 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $249.14 | 2 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $171.65 | 6 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $152.15 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $150.67 | 9 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $144.75 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $124.86 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $112.37 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $89.91 | 5 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $72.72 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $31.57 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $18.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 746 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
746 | 164 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
285 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
746 | 164 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 1521 | 444 |
| Amlodipine Besylate | Amlodipine Besylate | 1199 | 345 |
| Metoprolol Succinate | Metoprolol Succinate | 885 | 242 |
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 237 |
| Losartan Potassium | Losartan Potassium | 813 | 233 |
| Xarelto | Rivaroxaban | 770 | 169 |
| Eliquis | Apixaban | 746 | 164 |
| Metoprolol Tartrate | Metoprolol Tartrate | 576 | 166 |
| Furosemide | Furosemide | 544 | 171 |
| Lisinopril | Lisinopril | 468 | 142 |
| Carvedilol | Carvedilol | 448 | 112 |
| Potassium Chloride | Potassium Chloride | 418 | 134 |
| Spironolactone | Spironolactone | 414 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 96 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 310 | 81 |
| Entresto | Sacubitril/Valsartan | 285 | 63 |
| Clonidine Hcl | Clonidine Hcl | 236 | 106 |
| Warfarin Sodium | Warfarin Sodium | 223 | 67 |
| Atenolol | Atenolol | 214 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 54 |
| Simvastatin | Simvastatin | 203 | 58 |
| Farxiga | Dapagliflozin Propanediol | 171 | 36 |
| Nitroglycerin | Nitroglycerin | 169 | 92 |
| Chlorthalidone | Chlorthalidone | 167 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 48 |
| Prasugrel Hcl | Prasugrel Hcl | 161 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 36 |
| Torsemide | Torsemide | 118 | 45 |
| Amiodarone Hcl | Amiodarone Hcl | 115 | 42 |
| Omeprazole | Omeprazole | 115 | 33 |
| Sotalol | Sotalol Hcl | 111 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 36 |
| Ranolazine Er | Ranolazine | 102 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 30 |
| Digoxin | Digoxin | 97 | 27 |
| Ezetimibe | Ezetimibe | 90 | 24 |
| Gabapentin | Gabapentin | 85 | 24 |
| Repatha Sureclick | Evolocumab | 75 | 14 |
| Dofetilide | Dofetilide | 69 | 14 |
| Bumetanide | Bumetanide | 68 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 20 |
| Nifedipine Er | Nifedipine | 65 | 20 |
| Dilt-Xr | Diltiazem Hcl | 63 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 23 |
| Verapamil Er | Verapamil Hcl | 62 | 19 |
| Clonidine | Clonidine | 60 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 55 | 17 |
| Verapamil Sr | Verapamil Hcl | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 19 |
| Diazepam | Diazepam | 42 | 31 |
| Flecainide Acetate | Flecainide Acetate | 42 | 12 |
| Multaq | Dronedarone Hcl | 39 | suppressed |
| Brilinta | Ticagrelor | 38 | 11 |
| Cilostazol | Cilostazol | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | 12 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Prednisone | Prednisone | 32 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 23 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vyndamax | Tafamidis | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Inpefa | Sotagliflozin | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,772.36 · 66 records | Shockwave Medical, Inc | AVEIR, Asahi Coronary Wires, Asahi Peripheral Vascular Wires, CAMZYOS, ELIQUIS, EkoSonic, FARAPULSE, GORE VIABAHN VBX Balloon Expandable Endo, General - Stents, LEQVIO, MITRACLIP, ROTAPRO, RotarexS 6 F x 135 cm, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, WAINUA, WATCHMAN, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error